A major goal of aging research is to understand the underlying relationship between nutritional intake, metabolism, and healthy aging. Low-glycemic index diets have been shown to reduce risk of age-related metabolic diseases such as diabetes and cardiovascular disease, and reduced caloric intake via dietary restriction (DR) increases healthspan across species. One potential approach for supporting healthy aging is via interventions that engage healthspan-promoting metabolism.Our previous work has shown that interventions that block glycolysis result in striking healthspan gains, while increased gluconeogenic activity can similarly promote healthy aging. We have also shown that DR increases healthspan in a manner that requires gluconeogenic gene expression. These results suggest that molecular pathways that engage gluconeogenic metabolism and inhibit glycolysis may generally work to improve the quality of aging. In mammals, the glucagon signaling pathway works opposite to the insulin pathway to regulate blood sugar levels: when circulating glucose levels are low, glucagon promotes glucose production in the liver by stimulating glycogenolysis and gluconeogenesis while inhibiting glycogen synthesis and glycolysis. We reason that glucagon signaling, like DR (and unlike insulin signaling), may have an overall positive impact on healthspan. To investigate this, we screened for potential glucagon receptors in Caenorhabditis elegans, and found one candidate,
pdfr-1, which is required for the induction of gluconeogenic gene expression under DR and for the long lifespan of dietary-restricted animals. In the mammalian glucagon signaling pathway, the G protein alpha subunit coupled to the glucagon receptor activates adenylate cyclase, which increases cAMP levels to activate protein kinase A, which in turn inhibits glycolytic activity and promotes gluconeogenesis. Similar to
pdfr-1, we find that a C. elegans adenylate cyclase ortholog,
acy-1, is required for increased lifespan under DR. We also find that disruption of
kin-2, which encodes the inhibitory subunit of the C. elegans PKA ortholog
kin-1, triggers biomarkers for the DR state and results in dramatic healthspan increases that mirror those seen under DR. Our observations reveal a potential C. elegans glucagon pathway that is required for DR healthspan benefits, and suggest novel approaches to improving the quality of aging via interventions that promote glucagon pathway signaling.